Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Phuong T Vo, Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Chris Davis, Ryan S. Basom, Rainer F. Storb, Roland B. Walter

Blood (2024) 144 (Supplement 1): 7314.

https://doi.org/10.1182/blood-2024-206221

Published: 2024

Journal Articles

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Daniel J. Olivieri, Alexis Berridge-Green, Megan Othus, Anna B. Moseley, Jerald P. Radich, Anjali S. Advani, Harry P. Erba, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2024-199817

Published: 2024

Journal Articles

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

Suravi Raychaudhuri, Ted Gooley, Megan Othus, Xiaoyu Qu, Carole Shaw, Kathryn Russell, Rutu D. Vyas, Jacob S. Appelbaum, Anna B. Halpern, Roland B. Walter, Harry P. Erba, Min Fang, Mary-Elizabeth M. Percival

Blood (2024) 144 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2024-201213

Published: 2024

Journal Articles

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Blood (2024) 144 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2024-198506

Published: 2024

Journal Articles

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Daniel J Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Irum Khan, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2023-181244

Published: 2023

Journal Articles

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Michelle Y. Zhang, Megan Othus, Kerry K McMillen, Harry P. Erba, Guillermo Garcia-Manero, John Pagel, Mohamed Sorror, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2023-189455

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

Journal Articles

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Anjali S. Advani, Anna B Moseley, Kristen M. O'Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M Stone, Elad Sharon, Cecilia C.S. Yeung, Jerald P. Radich, Harry P. Erba

Blood (2023) 142 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2023-180204

Published: 2023

Journal Articles

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

Noam E. Kopmar, Megan Othus, Olivia Gilbert, Kelda Schonhoff, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Paul C. Hendrie, Bart L. Scott, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 3199–3201.

https://doi.org/10.1182/blood-2022-166526

Published: 2022

Journal Articles

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alexander J. Ambinder, Andrew M. Brunner, Mary-Elizabeth M. Percival, Christopher S. Hourigan, Ronan Swords, Amy E. DeZern, Elihu H. Estey, Judith E. Karp

Blood (2022) 140 (Supplement 1): 1430–1432.

https://doi.org/10.1182/blood-2022-164739

Published: 2022

Journal Articles

Time to Count Recovery after Post-Remission Chemotherapy in AML Patients

Gabrielle Paras, Megan Othus, Carole M. Shaw, Katie Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul C. Hendrie, Roland B. Walter, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 6080–6081.

https://doi.org/10.1182/blood-2022-157586

Published: 2022

Journal Articles

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Anna B. Halpern, Eduardo P Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Sioban B. Keel, Paul C. Hendrie, Bart L. Scott, Cristina Ghiuzeli, Roland B. Walter, Elihu H. Estey

Blood (2022) 140 (Supplement 1): 8999–9001.

https://doi.org/10.1182/blood-2022-159882

Published: 2022

Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood (2022) 140 (Supplement 1): 9057–9060.

https://doi.org/10.1182/blood-2022-169307

Published: 2022

Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus

Blood (2022) 140 (Supplement 1): 8932–8933.

https://doi.org/10.1182/blood-2022-170376

Published: 2022

Journal Articles

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood (2022) 140 (Supplement 1): 745–747.

https://doi.org/10.1182/blood-2022-162526

Published: 2022

Journal Articles

Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia

John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 132–134.

https://doi.org/10.1182/blood-2022-169801

Published: 2022

Journal Articles

A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

Jason E Farrar, Jenny L. Smith, Megan Othus, Benjamin J. Huang, Yi-Cheng Wang, Rhonda E. Ries, Tiffany A. Hylkema, Era L Pogosova-Agadjanyan, Sneha Challa, Amanda R. Leonti, Timothy I. Shaw, Timothy Junius Triche, Jr., Alan S. Gamis, Richard Aplenc, Anders E. Kolb, Xiaotu Ma, Derek Stirewalt, Todd A. Alonzo, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 9173–9174.

https://doi.org/10.1182/blood-2022-168296

Published: 2022

Journal Articles

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Gabrielle Paras, Linde M. Morsink, Megan Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary Schoch, Chris Davis, Marie Bleakley, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter

Blood (2022) 139 (11): 1694–1706.

https://doi.org/10.1182/blood.2021014804

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, Megan Othus, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bart L. Scott, Jacob S. Appelbaum, Anna B. Halpern, Vivian G. Oehler, Johnnie J. Orozco, Sioban B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Kaysey F. Orlowski, Anise J. Marshall, Clarisa N. Brown, Elihu H. Estey, Roland B. Walter

Blood (2021) 138 (Supplement 1): 34.

https://doi.org/10.1182/blood-2021-151658

Published: 2021

Journal Articles

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba

Blood (2021) 138 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2021-145529

Published: 2021

NARROW

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Time to Count Recovery after Post-Remission Chemotherapy in AML Patients

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia

A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only